Original Research
Published on 24 May 2024
Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States
in Cancer Immunity and Immunotherapy
- 6,244 views
- 1 citation